The Real-world Efficacy and Safety of Anlotinib in Advanced Non-small Cell Lung Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2021 Aug 6

PMID 34357411

Citations 8

Authors

Fen Wang

Feng Jin

Boran Cheng

Yue Zhang

Qing Zhou

Shubin Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world.

Methods: Patients with aNSCLC receiving anlotinib were enrolled in two cohorts (treatment naive and previously treated). The endpoints included progression-free survival (PFS), overall survival (OS) and anlotinib-related adverse events (ar-AEs).

Results: 203 patients accrued in the study. In the treatment-naïve cohort (n = 80), the PFS was 7.4 (95% confidence interval [CI] 4.1-10.7) and OS was 10.8 (95% CI 5.8-15.8) months of monotherapy group (immature survival for combination group). In previously treated cohort (n = 123), the PFS was 8.0 months (95% CI 6.1-9.9) in the combination group and 4.3 months (95% CI 2.1-6.6) in the monotherapy group (hazard ratio [HR] 0.49; 95% CI 0.29-0.83; p = 0.007), respectively. The OS was 18.5 months (95% CI 10.5-26.6) in the combination group and 7.8 months (95% CI 7.1-8.4) in the monotherapy group (HR 0.38; 95% CI 0.22-0.66; p = 0.001), respectively. The ar-AEs of grade ≥ 3 in the monotherapy and the combination groups were hypertension (9.0 and 8.7%), fatigue (8.1 and 7.6%), hand-foot syndrome (8.1 and 6.5%), diarrhea (5.4 and 8.7%), proteinuria (5.4 and 5.4%), and mucositis oral (6.3 and 8.7%).

Conclusion: In aNSCLC, anlotinib monotherapy has a promising efficacy in the first-line setting. It may be an option for those who are ineligible for chemotherapy; anlotinib combination therapy in a ≥ second-line setting showed manageable toxicities and encouraging efficacy, indicating a good application prospect.

Trial Registration: This study was retrospectively registered with ISRCTN Registry (ID ISRCTN35543977) on January 26th, 2021 and Chinese Clinical Trial Register (ChiCTR2000032265) on April 4th, 2020.

Citing Articles

The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer.

Wei X, Zhao Y, Yan W, Dai Q, Wu H, Miao Y Onco Targets Ther. 2024; 17:629-642.

PMID: 39131903 PMC: 11316477. DOI: 10.2147/OTT.S468932.

Long-term survival in a patient with metastatic parathyroid carcinoma harboring an sensitizing mutation: a case report.

Ying Y, Li H, Xia W, Cheng T, Li H, Fu Q J Int Med Res. 2024; 52(7):3000605241259669.

PMID: 39053452 PMC: 11283662. DOI: 10.1177/03000605241259669.

Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials.

Liu Y, Miao L, Chen X, Zhu X, Li Y, He J Medicine (Baltimore). 2024; 103(27):e38459.

PMID: 38968520 PMC: 11224810. DOI: 10.1097/MD.0000000000038459.

Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis.

Wu Z, Zhou P, Zhao Y, Wang J, Gao S Transl Cancer Res. 2024; 13(5):2451-2463.

PMID: 38881944 PMC: 11170544. DOI: 10.21037/tcr-23-1483.

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial.

Zhao D, Li Z, Hou X, Yang L, Li Z, Yan L Front Oncol. 2024; 14:1335009.

PMID: 38651156 PMC: 11033435. DOI: 10.3389/fonc.2024.1335009.

References

Alshangiti A, Chandhoke G, Ellis P . Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 2018; 25(Suppl 1):S45-S58. PMC: 6001774. DOI: 10.3747/co.25.3747. View

Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico L . Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res. 2010; 16(15):3887-900. DOI: 10.1158/1078-0432.CCR-09-3100. View

Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikstrom A, Chouaid C . Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014; 25(5):1044-52. DOI: 10.1093/annonc/mdu098. View

Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E . Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2012; 14(1):29-37. DOI: 10.1016/S1470-2045(12)70477-1. View

Chen K, Zhou L, Xie H, Ahmed T, Feng X, Zheng S . Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol. 2011; 29(3):1817-26. DOI: 10.1007/s12032-011-0006-x. View

Chen Y, Lai C, Chang H, Chao T, Tseng C, Fang W . Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One. 2015; 10(8):e0136252. PMC: 4552380. DOI: 10.1371/journal.pone.0136252. View

Chen D, Xu J, Zhao Y, Chu T, Zhong H, Han B . Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. J Cancer Res Clin Oncol. 2019; 146(2):401-406. DOI: 10.1007/s00432-019-03064-1. View

Chen Y, Yang Z, Wang Y, Hu M, Zhang B, Zhang Y . Pembrolizumab Plus Chemotherapy or Anlotinib Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. Front Oncol. 2021; 11:671228. PMC: 8085497. DOI: 10.3389/fonc.2021.671228. View

Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C . Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol. 2021; 16(4):643-652. DOI: 10.1016/j.jtho.2020.11.026. View

10.

Clear A, Lee A, Calaminici M, Ramsay A, Morris K, Hallam S . Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood. 2010; 115(24):5053-6. PMC: 2890144. DOI: 10.1182/blood-2009-11-253260. View

11.

De Boer R, Arrieta O, Yang C, Gottfried M, Chan V, Raats J . Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011; 29(8):1067-74. DOI: 10.1200/JCO.2010.29.5717. View

12.

Deme D, Telekes A . [Prognostic importance of albumin in oncology]. Orv Hetil. 2018; 159(3):96-106. DOI: 10.1556/650.2018.30885. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Fossella F, Pereira J, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E . Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21(16):3016-24. DOI: 10.1200/JCO.2003.12.046. View

15.

Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M . Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14):1505-1517. DOI: 10.1200/JCO.19.03136. View

16.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

17.

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

18.

Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M . Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28):2518-2527. PMC: 6768611. DOI: 10.1200/JCO.19.00934. View

19.

Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M . Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018; 36(17):1675-1684. DOI: 10.1200/JCO.2017.77.0412. View

20.

Go S, Kim R, Song H, Kang M, Lee U, Choi H . Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol. 2014; 31(12):323. DOI: 10.1007/s12032-014-0323-y. View